JW Therapeutics Says Beijing's Tech Scrutiny Has Not Disrupted Pharma Collaborations
JW Therapeutics' chief executive Leo Tian says the company's international collaborations, especially in cell and gene therapies, have not been affected by China’s recent tighter review of overseas technology transactions. While Beijing moved to unwind Meta's purchase of AI startup Manus, industry observers note growing interest from international …